Fosfomycin: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - "Category:Drugs" to "Category:Pharmacology") |
(Text replacement - "*Diarrhea" to "*Diarrhea") |
||
| Line 34: | Line 34: | ||
===Common=== | ===Common=== | ||
*Diarrhea | *[[Diarrhea]] | ||
*Vaginitis | *Vaginitis | ||
*Rhinitis | *Rhinitis | ||
Revision as of 16:28, 24 September 2016
General
- Type:
- Dosage Forms: PO
- Common Trade Names: Monurol
Adult Dosing
- Uncomplicated UTI: 3 g PO x 1
Pediatric Dosing
- Uncomplicated UTI:
>12 y/o: 3 g PO x 1
Special Populations
- Pregnancy Rating: B
- Lactation: Safety Unknown
- Renal Dosing
- Dose adjustment not necessary
- Hepatic Dosing
- Not Defined
Contraindications
- Allergy to class/drug
- Caution if hepatic impairment
- Caution if recent antibiotic-associated colitis
Adverse Reactions
Serious
- Angioedema
- Aplastic Anemia
- Asthma Exacerbation
- Hepatic Necrosis
- Toxic Megacolon
- C. difficile diarrhea
Common
- Diarrhea
- Vaginitis
- Rhinitis
- nausea
- headache
- dizziness
- back pain
- abdominal pain
- dysmenorrhea
Pharmacology
- Half-life: 5.7 hours
- Metabolism:
- Excretion: Urine 38%, Feces 18%
- Mechanism of Action: Bactericidal, inhibits cell wall synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
Source
- ↑ Sanford Guide to Antimicrobial Therapy 2014
- Epocrates 12/7/14
